Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Investing Activities (2018 - 2025)

UroGen Pharma's Cash from Investing Activities history spans 8 years, with the latest figure at $27.7 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 54.28% year-over-year to $27.7 million; the TTM value through Dec 2025 reached $61.6 million, up 398.64%, while the annual FY2025 figure was $61.6 million, 398.64% up from the prior year.
  • Cash from Investing Activities reached $27.7 million in Q4 2025 per URGN's latest filing, down from $31.4 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $60.6 million in Q4 2024 to a low of -$106.8 million in Q3 2024.
  • Average Cash from Investing Activities over 5 years is $2.3 million, with a median of $9.9 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: surged 2563.58% in 2023, then tumbled 26720.95% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $9.1 million in 2021, then soared by 153.24% to $23.1 million in 2022, then plummeted by 149.09% to -$11.3 million in 2023, then soared by 634.39% to $60.6 million in 2024, then plummeted by 54.28% to $27.7 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Cash from Investing Activities are $27.7 million (Q4 2025), $31.4 million (Q3 2025), and $28.4 million (Q2 2025).